Skip to main content

Table 4 Median survival and, 1-, 3-year OS of PDAC patients (n = 21,030)

From: Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis

TNM Stage

Treatments

Median survival

1-year OS

3-year OS

T1-3N0M0

Only surgery

21

70.14%

46.52%

 

Surgery + chemotherapy

25

73.27%

49.36%

 

Neoadjuvant radiotherapy

19

67.65%

39.87%

 

Adjuvant radiotherapy

24

72.09%

48.16%

T1-3N + M0

Only surgery

10

38.65%

6.88%

 

Surgery + chemotherapy

15

42.27%

14.85%

 

Neoadjuvant radiotherapy

16

39.26%

12.34%

 

Adjuvant radiotherapy

19

47.64%

18.63%

T4N0M0

Only surgery

7

27.14%

6.72%

 

Surgery + chemotherapy

17

47.67%

19.36%

 

Neoadjuvant radiotherapy

20

52.75%

26.47%

 

Adjuvant radiotherapy

14

31.82%

8.73%

T4N + M0

Only surgery

6

7.28%

0.05%

 

Surgery + chemotherapy

10

26.18%

6.54%

 

Neoadjuvant radiotherapy

17

42.34%

16.56%

 

Adjuvant radiotherapy

16

33.29%

9.86%

  1. PDAC Pancreatic Ductal Adenocarcinoma, OS Overall Survival